Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.60 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.50 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.49 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31560200 | 0.88 | CDK2 (0.61) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL5452864 | 0.88 | CDK2 (0.67) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL14427341 | 0.87 | CDK2 (0.76) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL5452944 | 0.86 | TP53 (0.61) | CDK2CCNE1KCNN3TP53 | |
| SCHEMBL5452857 | 0.82 | CDK2 (0.65) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL5458716 | 0.81 | CDK2 (0.56) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL5455497 | 0.81 | CDK2 (0.64) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL31560204 | 0.81 | CDK2 (0.55) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL14427337 | 0.80 | CDK2 (1.00) | CDK2CCNE1KCNN3KCNN1KCNN2 | |
| SCHEMBL5451908 | 0.80 | CDK2 (0.72) | CDK2CCNE1KCNN3KCNN1KCNN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | claimed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | claimed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | CDK2 284/4885CCNE1 223/4885KCNN3 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.